Table 1—

Baseline characteristics of study population

PlaceboRagaglitazar
Pioglitazone (45 mg)
0.1 mg1 mg4 mg10 mg
n302630323128
Age (years)54 (29–69)57 (37–70)56 (37–70)51 (37–73)55 (33–71)55 (40–71)
Sex (men/women)18/1212/1416/1415/1713/1811/17
BMI (kg/m2)31 (23–43)33 (23–46)31 (25–41)31 (25–38)32 (25–41)31 (12–43)
Previous therapy
 Diet/OHA12/186/2016/1410/228/236/22
A1C (%)8.1 (6–11)8.0 (6–10)8.4 (6–11)8.6 (6–12)7.7 (6–10)8.5 (7–11)
FPG (mg/dl)207 ± 42194 ± 44192 ± 44195 ± 42184 ± 39214 ± 43
Triglycerides (mg/dl)351 ± 168293 ± 95296 ± 175265 ± 102290 ± 131315 ± 122
  • Data are mean (range) or mean ± SD unless otherwise indicated.